| 301 |
17189388 | Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol. | 2006 Dec |
1 |
| 302 |
17212145 | [A case of advanced breast cancer with meningeal carcinomas and orbital metastasis successfully treated with multi-disciplinary therapy]. | 2006 Nov |
2 |
| 303 |
20859353 | Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study. | 2006 Nov |
4 |
| 304 |
15668276 | Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. | 2005 Feb |
2 |
| 305 |
15700118 | Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. | 2005 Feb |
8 |
| 306 |
15738535 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. | 2005 Jun 1 |
1 |
| 307 |
15941387 | HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. | 2005 Jun |
4 |
| 308 |
16110294 | Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery. | 2005 |
1 |
| 309 |
16115903 | Breast cancer molecular subtypes respond differently to preoperative chemotherapy. | 2005 Aug 15 |
1 |
| 310 |
16173788 | Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. | 2005 Sep-Oct |
1 |
| 311 |
16216740 | Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab. | 2005 Oct |
2 |
| 312 |
16360542 | Gemcitabine-taxane experience in the treatment of metastatic breast cancer. | 2005 |
1 |
| 313 |
16361156 | [Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu]. | 2005 Dec |
3 |
| 314 |
16381626 | Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. | 2005 Dec |
2 |
| 315 |
14710203 | Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. | 2004 Jan 12 |
3 |
| 316 |
15034952 | Trastuzumab in the treatment of advanced breast cancer. Our single-center experience and spotlights of the latest national consensus meeting. | 2004 |
1 |
| 317 |
15059359 | [Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer]. | 2004 Jan |
3 |
| 318 |
15117984 | Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. | 2004 May 1 |
1 |
| 319 |
15123142 | [Indications for Herceptin in breast cancer treatment]. | 2004 Feb |
1 |
| 320 |
15161043 | Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. | 2004 Mar-Apr |
2 |
| 321 |
15217493 | Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. | 2004 |
1 |
| 322 |
15292386 | Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. | 2004 Aug 4 |
1 |
| 323 |
15501983 | Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. | 2004 Oct 15 |
1 |
| 324 |
15581045 | Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). | 2004 |
1 |
| 325 |
15582895 | 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. | 2004 Oct |
2 |
| 326 |
12506169 | Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. | 2003 Jan 1 |
1 |
| 327 |
12576925 | Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. | 2003 Feb |
3 |
| 328 |
12603385 | Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer. | 2003 Mar-Apr |
1 |
| 329 |
12680177 | Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. | 2003 Jan-Feb |
2 |
| 330 |
12722021 | Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. | 2003 Apr |
1 |
| 331 |
12724856 | Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker. | 2003 Jan-Feb |
1 |
| 332 |
12761490 | HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. | 2003 May 22 |
1 |
| 333 |
12973835 | ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. | 2003 Sep 15 |
2 |
| 334 |
14507946 | Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. | 2003 Nov 1 |
1 |
| 335 |
14676119 | Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. | 2003 Dec 1 |
1 |
| 336 |
14768403 | Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. | 2003 Dec |
1 |
| 337 |
11790161 | Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. | 2002 |
1 |
| 338 |
11872285 | Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. | 2002 Feb 1 |
1 |
| 339 |
11881914 | Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens. | 2002 Jan |
1 |
| 340 |
12049736 | Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. | 2002 May |
3 |
| 341 |
12138396 | Trastuzumab/chemotherapy combinations in metastatic breast cancer. | 2002 Jun |
1 |
| 342 |
12209684 | Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? | 2002 Sep 1 |
2 |
| 343 |
12384528 | Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. | 2002 Oct 15 |
11 |
| 344 |
12419746 | In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. | 2002 Nov |
5 |
| 345 |
11208823 | Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. | 2001 Jan 15 |
1 |
| 346 |
11352950 | Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. | 2001 May 15 |
2 |
| 347 |
11464447 | From HER2 to herceptin. | 2001 |
1 |
| 348 |
11477443 | HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. | 2001 Apr |
2 |
| 349 |
11496337 | Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer. | 2001 Sep-Oct |
3 |
| 350 |
11521725 | Ongoing trials with trastuzumab in metastatic breast cancer. | 2001 |
3 |